Is Metformin Associated with a Lower Prevalence of Polyps, Adenomas, and Colorectal Carcinoma in Patients with Diabetes Mellitus?
- 21 November 2023
- journal article
- research article
- Published by Springer Nature in Journal of Gastrointestinal Cancer
- Vol. 55 (1) , 435-443
Abstract
Purpose Recent studies suggested a protective role of metformin in the development of colorectal cancer (CRC) and its precursors. We aimed to investigate if metformin was associated with a lower prevalence and number of colorectal polyps in diabetic patients and also adenomas, high-risk adenomas, and CRC. Methods Retrospective study on adult patients with diabetes mellitus followed in our hospital with a total colonoscopy between 2015 and 2019, treated with either metformin for > 5 years or other antidiabetic agent (control group). We assessed the number, size, and histopathology examination of proliferative lesions detected on colonoscopy. Results We included 401 patients aged 69 ± 9 years, 57% males, divided into two groups: treated with metformin (n = 260) and without (n = 141). The number of polyps detected was significantly lower in patients under metformin (p = 0.014). There was a nonsignificant trend towards lower polyp detection rates in the metformin compared to the control group both in unadjusted analysis (50% vs 60%, p = 0.058) and multivariable adjusted analysis (odds ratio [OR] 0.68, 95% confidence interval [CI] 0.43–1.09, p = 0.111). In the latter, we identified male gender (OR 2.24, 95%CI 1.44–3.49, p < 0.001), age (OR 1.35 for every 10 years, 95%CI 1.07–1.71, p = 0.012), glycated hemoglobin value (OR 1.20 for every 1% increase, 95%CI 1.06–1.37, p = 0.005), and hypertension (OR 1.76, 95%CI 1.01–3.08, p = 0.046) as factors associated with a higher prevalence of polyps. We saw no statistically significant differences regarding adenoma (p = 0.231), high-risk adenoma (p = 0.810), and CRC (p = 0.705) diagnoses between groups. Conclusion In our study, metformin was associated with less colorectal polyps in diabetic patients compared to other treatment modalities. We observed a nonsignificant trend towards lower polyp detection rates in the metformin group both in unadjusted and adjusted analyses.Keywords
All Related Versions
This publication has 44 references indexed in Scilit:
- The relationship between different glycemic statuses and colon polyps in a Taiwanese populationJournal of Gastroenterology, 2014
- HbA1c: A Review of Analytical and Clinical AspectsAnnals of Laboratory Medicine, 2013
- Relationship between type-2 diabetes and use of metformin with risk of colorectal adenoma in an American population receiving colonoscopyJournal of Diabetes and its Complications, 2013
- Association of Type 2 Diabetes and Colon AdenomasJournal of Gastrointestinal Cancer, 2011
- Hypertension is an independent risk factor for colorectal polyps: Table 1Gut, 2011
- The Boston bowel preparation scale: a valid and reliable instrument for colonoscopy-oriented researchGastrointestinal Endoscopy, 2009
- Obesity and Risk of Colorectal Cancer: A Meta-analysis of 31 Studies with 70,000 EventsCancer Epidemiology, Biomarkers & Prevention, 2007
- Serum Insulin Levels and the Prevalence of Adenomatous and Hyperplastic Polyps in the Proximal ColonClinical Gastroenterology and Hepatology, 2006
- Insulin-Like Growth Factor-I and Insulin Are Associated With the Presence and Advancement of Adenomatous PolypsGastroenterology, 2005
- Insulin, Insulin-Like Growth Factor-I (IGF-I), IGF Binding Proteins, Their Biologic Interactions, and Colorectal CancerJNCI: Journal of the National Cancer Institute, 2002